Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.58 |
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945663 | 0.83 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6945794 | 0.80 | SLC6A4 (0.69) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6947234 | 0.78 | SLC6A4 (0.65) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL14299109 | 0.77 | SLC6A4 (0.71) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL7211594 | 0.77 | SLC6A4 (0.69) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6943559 | 0.76 | SLC6A4 (0.69) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL13395735 | 0.76 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6947187 | 0.76 | SLC6A4 (0.70) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6945367 | 0.74 | SLC6A4 (0.59) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6947231 | 0.74 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A4 4537/4885HTR2A 4618/4885KCNH2 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.